• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Public Health . SARS-CoV-2 seroprevalence and antibody trajectories after easing of COVID-19 restrictions: a longitudinal study in China

tetano

Editor, Senior Moderator
Front Public Health


. 2024 Dec 3:12:1420993.
doi: 10.3389/fpubh.2024.1420993. eCollection 2024. SARS-CoV-2 seroprevalence and antibody trajectories after easing of COVID-19 restrictions: a longitudinal study in China

Feng Ling[SUP] #[/SUP][SUP] 1 2 [/SUP], Zenghao Xu[SUP] #[/SUP][SUP] 2 [/SUP], Jimin Sun[SUP] 2 [/SUP], Xiaoxiao Wang[SUP] 2 [/SUP], Yan Feng[SUP] 2 [/SUP], Ying Liu[SUP] 2 [/SUP], Yijuan Chen[SUP] 2 [/SUP], Jinna Wang[SUP] 2 [/SUP], Zhiping Chen[SUP] 2 [/SUP], Kun Chen[SUP] 1 [/SUP]



Affiliations
Free PMC article Abstract

Background: We aimed to evaluate the seroprevalence of SARS-CoV-2 and investigate the trajectories of protective immunity and associated risk factors in eastern China between March and November 2023 after the easing of COVID-19 restrictions.
Materials and methods: We conducted repeated population-based seroepidemiologic studies using a multistage, population-stratified, cluster random sampling method. We measured neutralizing antibodies (nAbs) using a fluorescence immunoassay. We calculated both overall and stratified seroprevalence. The latent class growth mixed model (LCGMM) was used to analyze the dynamic trajectories of antibodies, and a multinomial logistic regression model was used to identify factors associated with different antibody trajectory patterns.
Results: A total of 6,147 participants were included at baseline, with a median age of 53.61 years. Both observed and adjusted seroprevalence remained high and stable throughout the study period. The LCGMM identified four distinct antibody trajectories: 75.22% of participants had a high and stable antibody trajectory, while nearly 8% of them exhibited an increase, decline, or low-stable antibody trajectory. Younger participants, women, those fully vaccinated, and individuals with a history of previous infection were more likely to have high and stable antibody trajectories.
Conclusion: The majority of the population maintained sustained protective immunity after the outbreak, following the easing of COVID-19 restrictions across the country.

Keywords: COVID-19; China; SARS-CoV-2; risk factor; seroprevalence; trajectory.

 
Back
Top Bottom